Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online January 9, 2008
Diabetes Care 31:758-760, 2008
DOI: 10.2337/dc07-1544
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
dc07-1544v1
31/4/758    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adya, R.
Right arrow Articles by Randeva, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adya, R.
Right arrow Articles by Randeva, H. S.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Pathophysiology/Complications
Original Research

Nuclear Factor-{kappa}B Induction by Visfatin in Human Vascular Endothelial Cells

Its role in MMP-2/9 production and activation

Raghu Adya, MBBS, MSC, Bee K. Tan, MBBS, Jing Chen, PHD and Harpal S. Randeva, MBCHB, FRCP, MD, PHD

From the Endocrinology & Metabolism Group, Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, U.K.

Address correspondence and reprint requests to Dr. Harpal S. Randeva, MBCHB, FRCP, MD, PhD, Endocrinology & Metabolism Group, Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry CV4 7AL, U.K. E-mail: harpal.randeva{at}warwick.ac.uk

OBJECTIVE—Visfatin is elevated in obesity and type 2 diabetes and is thought to be an inflammatory mediator within atherosclerotic lesions and to induce gelatinase activity. We investigated the activation of nuclear factor-{kappa}B (NF-{kappa}B), a well-known proinflammatory transcription factor, by visfatin in endothelial cells.

RESEARCH DESIGN AND METHODS—Human endothelial cells were transfected with pNF-{kappa}B-Luc plasmid. Using quantitative PCR, Western blot analysis, and gelatin zymography, we studied NF-{kappa}B signaling in gelatinase-mediated vascular inflammation by visfatin using the NF-{kappa}B inhibitor BAY 11-7085.

RESULTS—Visfatin significantly increased NF-{kappa}B transcriptional activity (P < 0.001). We also found a significant inhibition of tumor necrosis factor-{alpha} (TNF-{alpha})-induced NF-{kappa}B activity by visfatin (P < 0.001). Furthermore, the NF-{kappa}B inhibitor significantly negated visfatin-induced matrix metalloproteinase (MMP)-2/9 mRNA expression, protein levels, and gelatinolytic activity (P < 0.001).

CONCLUSIONS—Visfatin-induced NF-{kappa}B signaling in human endothelial cells affects the activation of gelatinases MMP-2 and -9, suggesting an important role of visfatin in the pathogenesis of vascular inflammation in obesity and type 2 diabetes.

Abbreviations: HUVEC, human umbilical vein endothelial cell • MMP, matrix metalloproteinase • NF-{kappa}B, nuclear factor-{kappa}B • TNF-{alpha}, tumor necrosis factor-{alpha}


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.